Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482926 | 0.72 | ATM (0.47) | GPR84 | |
| SCHEMBL1239890 | 0.71 | GPR84 (0.67) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL29356418 | 0.71 | GPR84 (0.67) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL12894952 | 0.71 | GPR84 (0.67) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL29989075 | 0.69 | GPR84 (0.65) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL3928782 | 0.68 | GPR84 (0.36) | GPR84 | |
| SCHEMBL21380893 | 0.68 | FFAR1 (0.36) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL11370107 | 0.68 | ALDH1A1 (0.38) | HTR2AHTR2CHTR2BGPR84ADRB1 | |
| SCHEMBL25399539 | 0.66 | CYP1A2 (0.41) | ADRA2ACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL9683618 | 0.66 | CYP1A2 (0.41) | ADRA2ACYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017991-B2 | Quaternary tryptamines and their therapeutic uses | CAAMTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12006290-B2 | Crystalline norpsilocin compounds | CAAMTECH, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240166600-A1 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | CAAMTECH, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240158349-A1 | TRYPTAMINE DERIVATIVES AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240116867-A1 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240116868-A1 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | CAAMTECH,INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240083848-A1 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | CAAMTECH INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11926590-B2 | Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts | CAAMTECH, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240050502-A1 | AMANITA MUSCARIA COMPOUNDS | CAAMTECH, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240043380-A1 | CRYSTALLINE BUFOTENIDINE COMPOUNDS | CAAMTECH, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230406824-A1 | TRYPTAMINE DERIVATIVES AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230348383-A1 | CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS | CAAMTECH, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230331671-A1 | CRYSTALLINE DIMETHYL TRYPTAMINE ANALOGUES | CAMTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11753375-B2 | Crystalline psilacetin derivatives | CAAMTECH, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11739060-B2 | Crystalline 5-methoxy-n,n-diallyltryptamine compounds | CAAMTECH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230126343-A1 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | CAAMTECH, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230123250-A1 | CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS | CAAMTECH, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230112410-A1 | CRYSTALLINE NORPSILOCIN COMPOUNDS | CAAMTECH, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230000885-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-01-05 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348383-A1 | CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS | HTR5A, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 10/4885 |
| US-12017991-B2 | Quaternary tryptamines and their therapeutic uses | HTR5A, HTR1B, HTR3B | HTR2A 4/4885HTR2C 16/4885HTR2B 6/4885 |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR2A 6/4885HTR2C 8/4885HTR2B 11/4885 |
| US-20240116867-A1 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | SLC18A1, HNMT, TPH1 | HTR2A 17/4885HTR2C 36/4885HTR2B 25/4885 |
| US-20230112410-A1 | CRYSTALLINE NORPSILOCIN COMPOUNDS | SLC6A4, HTR4, HNMT | HTR2A 8/4885HTR2C 6/4885HTR2B 4/4885 |
| US-11739060-B2 | Crystalline 5-methoxy-n,n-diallyltryptamine compounds | HTR5A, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 10/4885 |
| US-20240043380-A1 | CRYSTALLINE BUFOTENIDINE COMPOUNDS | HTR3B, HTR4, HTR5A | HTR2A 8/4885HTR2C 10/4885HTR2B 13/4885 |
| US-20240158349-A1 | TRYPTAMINE DERIVATIVES AND THEIR THERAPEUTIC USES | TPSB2, TPSAB1, TPSG1 | HTR2A 8/4885HTR2C 17/4885HTR2B 22/4885 |
| US-20230331671-A1 | CRYSTALLINE DIMETHYL TRYPTAMINE ANALOGUES | HNMT, INMT, PNMT | HTR2A 40/4885HTR2C 61/4885HTR2B 48/4885 |
| US-20240116868-A1 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | TPSG1, TPSB2, TPSD1 | HTR2A 19/4885HTR2C 79/4885HTR2B 68/4885 |
| US-12006290-B2 | Crystalline norpsilocin compounds | SLC6A4, HTR4, HNMT | HTR2A 8/4885HTR2C 6/4885HTR2B 4/4885 |
| US-20230406824-A1 | TRYPTAMINE DERIVATIVES AND THEIR THERAPEUTIC USES | TPSB2, TPSAB1, TPSG1 | HTR2A 9/4885HTR2C 23/4885HTR2B 24/4885 |
| US-11926590-B2 | Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts | SLC6A4, HTR4, HNMT | HTR2A 17/4885HTR2C 11/4885HTR2B 14/4885 |
| US-20240050502-A1 | AMANITA MUSCARIA COMPOUNDS | HTR3A, MANBA, MGAT2 | HTR2A 12/4885HTR2C 86/4885HTR2B 28/4885 |
| US-20230123250-A1 | CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS | HTR5A, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 10/4885 |
| US-11753375-B2 | Crystalline psilacetin derivatives | SLC6A4, PCMT1, HTR4 | HTR2A 26/4885HTR2C 40/4885HTR2B 62/4885 |
| US-20240166600-A1 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | SLC6A4, HTR4, TPH1 | HTR2A 16/4885HTR2C 11/4885HTR2B 14/4885 |
| US-20240083848-A1 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | TPSB2, HNMT, TPH1 | HTR2A 10/4885HTR2C 25/4885HTR2B 20/4885 |
| US-20230126343-A1 | CRYSTALLINE 4-HYDROXY-N,N-DI-N-PROPYLTRYPTAMMONIUM (4-HO-DPT) SALTS | SLC6A4, HTR4, HNMT | HTR2A 17/4885HTR2C 11/4885HTR2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.